^
Association details:
| Biomarker: | ROS1 rearrangement |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Rozlytrek (entrectinib) (ALK inhibitor, TrkB receptor inhibitor, TrkC kinase inhibitor, TrkA receptor inhibitor, ROS1 inhibitor, JAK2 inhibitor, TNK2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
11/25/2020
Excerpt:
Non-Small Cell Lung Cancer: ROS1 rearrangement positive...ROS1 rearrangement discovered prior to first-line systemic therapy…Preferred...Entrectinib
Source:
Title:
Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)
Excerpt:
...prior treatment with crizotinib is permitted only in ALK- or ROS1-rearranged NSCLC patients presenting with CNS-only progression....
Trial ID:
Source:
Title:
Alka-372-001: First-in-human, phase I study of entrectinib – an oral pan-trk, ROS1, and ALK inhibitor – in patients with advanced solid tumors with relevant molecular alterations.
Excerpt:
...Pts with advanced solid tumors with molecular alterations in TrkA, ROS1 or ALK were treated in Sch B (QD) or Sch C (4d on/3d off)...Entrectinib is well tolerated. The majority of pts reported G1/ G2 AEs. 13 pts reported ≥ G3 AEs….In this trial with entrectinib administered in 3 different dosing schedules, significant antitumor response was observed in pts with relevant molecular alterations, notably ROS1 rearranged NSCLC at doses ≥ 400 mg/m2/day and the only NTRK1 rearranged pt treated to date.
DOI:
10.1200/jco.2015.33.15_suppl.2517
Trial ID:
